AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
AAPL   321.50 (-0.11%)
MSFT   183.00 (-0.04%)
AMZN   2,458.95 (-0.49%)
CGC   16.35 (-0.79%)
BABA   211.70 (+2.48%)
GE   6.99 (+3.40%)
T   30.90 (-0.10%)
ACB   14.00 (-0.71%)
GILD   74.20 (-1.29%)
BAC   25.19 (+2.48%)
BA   155.30 (+2.58%)
Log in

NASDAQ:PRVBProvention Bio Stock Price, Forecast & News

$13.88
+0.18 (+1.31 %)
(As of 06/2/2020 10:07 AM ET)
Add
Compare
Today's Range
$13.43
Now: $13.88
$14.10
50-Day Range
$8.82
MA: $12.21
$14.31
52-Week Range
$4.00
Now: $13.88
$22.82
Volume44,067 shs
Average Volume430,087 shs
Market Capitalization$662.52 million
P/E RatioN/A
Dividend YieldN/A
Beta3.99
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company has a licensing and co-development agreement with Amgen Inc. for AMG 714. The company was incorporated in 2016 and is based in Oldwick, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRVB
CUSIPN/A
CIKN/A
Phone908-336-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.72 per share

Profitability

Net Income$-43,280,000.00

Miscellaneous

Employees13
Market Cap$662.52 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive PRVB News and Ratings via Email

Sign-up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter.

Provention Bio (NASDAQ:PRVB) Frequently Asked Questions

How has Provention Bio's stock been impacted by COVID-19 (Coronavirus)?

Provention Bio's stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRVB shares have increased by 54.0% and is now trading at $13.8776. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Provention Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Provention Bio.

When is Provention Bio's next earnings date?

Provention Bio is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Provention Bio.

How were Provention Bio's earnings last quarter?

Provention Bio Inc (NASDAQ:PRVB) announced its earnings results on Thursday, May, 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. View Provention Bio's earnings history.

What price target have analysts set for PRVB?

4 brokerages have issued 1 year price objectives for Provention Bio's stock. Their forecasts range from $20.00 to $35.00. On average, they expect Provention Bio's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 98.2% from the stock's current price. View analysts' price targets for Provention Bio.

Has Provention Bio been receiving favorable news coverage?

News stories about PRVB stock have trended very positive recently, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Provention Bio earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutProvention Bio.

Are investors shorting Provention Bio?

Provention Bio saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,760,000 shares, an increase of 13.1% from the April 30th total of 2,440,000 shares. Based on an average daily volume of 578,400 shares, the days-to-cover ratio is currently 4.8 days. Approximately 8.1% of the shares of the stock are short sold. View Provention Bio's Current Options Chain.

Who are some of Provention Bio's key competitors?

What other stocks do shareholders of Provention Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include Amarin (AMRN), Axsome Therapeutics (AXSM), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Myovant Sciences (MYOV), VBI Vaccines (VBIV), NVIDIA (NVDA), Opko Health (OPK), Vaxart (VXRT) and Clovis Oncology (CLVS).

Who are Provention Bio's key executives?

Provention Bio's management team includes the following people:
  • Mr. Ashleigh Palmer B.Sc., M.B.A., Co-Founder, Pres, CEO & Director (Age 56)
  • Mr. Francisco Leon M.D., Ph.D., Co-Founder, Chief Scientific Officer & Director (Age 47)
  • Mr. Andrew T. Drechsler, Chief Financial Officer (Age 47)
  • Dr. Eleanor L. Ramos, Chief Medical Officer & COO (Age 63)
  • Mr. Cameron Gray Ph.D., MD & Director (Age 46)

What is Provention Bio's stock symbol?

Provention Bio trades on the NASDAQ under the ticker symbol "PRVB."

Who are Provention Bio's major shareholders?

Provention Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (6.31%), BlackRock Inc. (1.43%), Invesco Ltd. (1.06%), Geode Capital Management LLC (0.61%), Segantii Capital Management Ltd (0.60%) and EAM Global Investors LLC (0.30%). Company insiders that own Provention Bio stock include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel and Wayne Pisano. View institutional ownership trends for Provention Bio.

Which major investors are selling Provention Bio stock?

PRVB stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Baker Avenue Asset Management LP, Lido Advisors LLC, Wells Fargo & Company MN, Bailard Inc., Virtus ETF Advisers LLC, State Street Corp, and Sigma Planning Corp. View insider buying and selling activity for Provention Bio.

Which major investors are buying Provention Bio stock?

PRVB stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., EAM Global Investors LLC, EAM Investors LLC, Perceptive Advisors LLC, Sontag Advisory LLC, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, and Jane Street Group LLC. Company insiders that have bought Provention Bio stock in the last two years include Andrew T Drechsler, Anthony Digiandomenico, Ashleigh Palmer, Avery W Catlin, Eleanor Ramos, Francisco Leon, Jason Hoitt, Peter A Appel, and Wayne Pisano. View insider buying and selling activity for Provention Bio.

How do I buy shares of Provention Bio?

Shares of PRVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Provention Bio's stock price today?

One share of PRVB stock can currently be purchased for approximately $13.88.

How big of a company is Provention Bio?

Provention Bio has a market capitalization of $662.52 million. The company earns $-43,280,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. Provention Bio employs 13 workers across the globe.

What is Provention Bio's official website?

The official website for Provention Bio is www.proventionbio.com.

How can I contact Provention Bio?

Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The company can be reached via phone at 908-336-0360 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.